Quick Answer
LENZ Therapeutics, Inc. reported R&D Expense of $18.67 million for fiscal year 2025.
LENZ Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $18.67M | -37.4% |
| 2024 | $29.80M | -49.9% |
| 2023 | $59.50M | -18.2% |
| 2022 | $72.79M | +91.9% |
| 2021 | $37.93M | +315.8% |
| 2020 | $9.12M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.79M | -41.2% | -58.2% |
| June 30, 2025 | $9.06M | +30.5% | +55.7% |
| March 31, 2025 | $5.82M | -44.8% | -9.8% |
| September 30, 2024 | $6.45M | -62.1% | -7.1% |
| June 30, 2024 | $6.95M | -45.1% | -34.1% |
| March 31, 2024 | $10.54M | +2.1% | -38.0% |
| September 30, 2023 | $17.00M | -7.1% | +34.5% |
| June 30, 2023 | $12.64M | -28.9% | +22.4% |
- LENZ Therapeutics, Inc. showed a decrease of -37.4% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, LENZ Therapeutics, Inc.’s r&d expense has grown by 104.6% (from $9.12 million to $18.67 million).
- The most recent figure is from LENZ Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: